Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Investment analysts at Lifesci Capital lifted their Q1 2025 earnings per share estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now expects that the biopharmaceutical company will post earnings per share of ($2.74) for the quarter, up from their prior estimate of ($2.95). The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($3.00) EPS, Q3 2025 earnings at ($3.28) EPS, Q4 2025 earnings at ($3.59) EPS and FY2025 earnings at ($12.62) EPS.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.24.
CRBP has been the subject of several other research reports. Jefferies Financial Group decreased their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday, March 6th. William Blair began coverage on Corbus Pharmaceuticals in a research report on Friday, February 28th. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $59.13.
Get Our Latest Stock Report on Corbus Pharmaceuticals
Corbus Pharmaceuticals Trading Down 9.1 %
CRBP stock traded down $0.63 during trading hours on Friday, hitting $6.33. 309,335 shares of the stock traded hands, compared to its average volume of 365,581. The stock has a 50-day simple moving average of $9.32 and a 200 day simple moving average of $18.10. Corbus Pharmaceuticals has a one year low of $6.26 and a one year high of $61.90. The company has a market cap of $77.09 million, a P/E ratio of -1.35 and a beta of 2.63.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Vestcor Inc bought a new position in Corbus Pharmaceuticals in the 3rd quarter worth approximately $64,000. Wells Fargo & Company MN grew its holdings in shares of Corbus Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 2,195 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter worth approximately $84,000. Deutsche Bank AG grew its holdings in shares of Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 2,616 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter worth approximately $101,000. 64.64% of the stock is owned by institutional investors.
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Featured Articles
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
